793279--10/1/2009--CANDELA_CORP

related topics

{product, liability, claim}

{property, intellectual, protect}

{cost, operation, labor}

{control, financial, internal}

{acquisition, growth, future}

{stock, price, operating}

{regulation, government, change}

{cost, contract, operation}

{investment, property, distribution}

{product, market, service}

{personnel, key, retain}

{operation, international, foreign}

{product, candidate, development}

The ability to complete the merger is subject to the receipt of consents and approvals from government entities, which may impose conditions that could have an adverse effect on us or could cause either party to abandon the merger. Any delay in completion of the merger may significantly reduce the benefits expected to be obtained from the merger. The anticipated benefits of the merger may not be realized fully or at all or may take longer to realize than expected. Failure to complete the merger for regulatory or other reasons could adversely affect our stock price and our future business and financial results. Unfavorable results in our intellectual property litigation with Palomar Medical Technologies may result in significant decline to our stock price or have a material affect on results of operations or on cash flows. We depend on sales from outside the United States that could be adversely affected by changes in international markets. The failure to obtain Alexandrite rods for the GentleLASE and the AlexTriVantage systems from our sole supplier would impair our ability to manufacture and sell these systems. Disappointing quarterly revenue or operating results could cause the price of our common stock to fall. Our failure to respond to rapid changes in technology and intense competition in the laser industry could make our lasers obsolete. Like other companies in our industry, we are subject to a regulatory review process and our failure to receive necessary government clearances or approvals could affect our ability to sell our products and remain competitive. We have modified some of our products without FDA clearance. The FDA could retroactively decide the modifications were improper and require us to cease marketing and/or recall the modified products. Achieving complete compliance with FDA regulations is difficult, and if we fail to comply, we could be subject to FDA enforcement action. We may also be subject to state regulations. State regulations, and changes to state regulations, may prevent sales to particular end users or may restrict use of the products to particular end users or under particular supervision which may decrease revenues or prevent growth of revenues. Claims by others that our products infringe their patents or other intellectual property rights could prevent us from manufacturing and selling some of our products or require us to incur substantial costs from litigation or development of non-infringing technology. We could incur substantial costs as a result of product liability claims. We may be unable to attract and retain management and other personnel we need to succeed. Our failure to manage future acquisitions and joint ventures effectively may divert management attention from our core business and cause us to incur additional debt, liabilities or costs. We face risks associated with product warranties The expense and potential unavailability of insurance coverage for our customers could adversely affect our ability to sell our products and negatively impact our financial condition. Failure to maintain effective internal control over financial reporting could have a material adverse effect on our business, operating results and stock price.

Full 10-K form ▸

793279--10/1/2009--CANDELA_CORP_/DE/